The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2020 | NGS: changes in CLL management
Richard Rosenquist Brandell, MD, of Karolinska Institute, Solna, Stockholm, discusses how the management of chronic lymphocytic leukemia (CLL) has changed since the advent of next-generation techniques as well as gene panel assays currently used for CLL prognosis and resistance assesment. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
